# Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. is a company headquartered in Cambridge, MA, United States.

## Company overview

- **Legal name:** Syros Pharmaceuticals, Inc.
- **Former names in filing history:** LS22, Inc. (2012-08-22 to 2012-08-22)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Cambridge, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001556263

## About

Syros Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001556263, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-27, it reported annual revenue of USD 9,936,000; net income of USD -164,574,000; total assets of USD 168,174,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $9.9M (USD 9,936,000)
- **Net income:** -$164.6M (USD -164,574,000)
- **Total assets:** $168.2M (USD 168,174,000)
- **Cash and equivalents:** $139.5M (USD 139,526,000)
- **Operating cash flow:** -$109.7M (USD -109,707,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $14.9M (USD 14,880,000)
- **Net income:** -$94.7M (USD -94,654,000)
- **Total assets:** $244.5M (USD 244,486,000)
- **Cash and equivalents:** $167.5M (USD 167,467,000)
- **Operating cash flow:** -$123.1M (USD -123,065,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $23.5M (USD 23,488,000)
- **Net income:** -$86.6M (USD -86,558,000)
- **Total assets:** $182.9M (USD 182,935,000)
- **Cash and equivalents:** $92.3M (USD 92,302,000)
- **Operating cash flow:** -$99.5M (USD -99,540,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2020 (period ended 2020-12-31)

- **Revenue:** $15.1M (USD 15,093,000)
- **Net income:** -$84.0M (USD -84,038,000)
- **Total assets:** $213.3M (USD 213,250,000)
- **Cash and equivalents:** $174.0M (USD 173,984,000)
- **Operating cash flow:** -$57.4M (USD -57,364,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2025-03-04 — period 2025-02-28 — 8-K
- Form 8-K — filed 2025-02-28 — period 2025-02-28 — 8-K
- Form 8-K — filed 2025-01-08 — period 2025-01-06 — 8-K
- Form 8-K — filed 2024-12-06 — period 2024-12-04 — 8-K
- Form 8-K — filed 2024-11-18 — period 2024-11-12 — 8-K
- Form 8-K — filed 2024-11-13 — period 2024-11-12 — 8-K
- Form 10-Q — filed 2024-10-31 — period 2024-09-30 — 10-Q
- Form 8-K — filed 2024-09-05 — period 2024-09-04 — 8-K
- Form 8-K — filed 2024-08-12 — period 2024-08-12 — 8-K
- Form 10-Q — filed 2024-07-31 — period 2024-06-30 — 10-Q
- Form 8-K — filed 2024-06-06 — period 2024-06-05 — FORM 8-K
- Form 10-Q — filed 2024-05-14 — period 2024-03-31 — 10-Q

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/syros-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology